Insider transactions

Robert J Hugin

CIK 1232505 · see remarks · last filed 2026-05-26

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$8.82M
Companies
8
Total Filings
117
Lifetime Open-Market Net
-$160.24M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

CELG price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O THE MEDICINES CO
8 CAMPUS DR
PARSIPPANY, NJ 07054
Related Filers
CELGENE CORP /DE/ — 110 joint filings, latest 2018-01-31
ACE LTD — 8 joint filings, latest 2026-05-26
Biohaven Pharmaceutical Holding Co Ltd. — 8 joint filings, latest 2022-10-03
Actavis plc — 5 joint filings, latest 2020-05-11
DANAHER CORP /DE/ — 5 joint filings, latest 2017-05-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CB Director 21,851 $359.79 $7.86M $0 7 2026-05-26
BHVN Director 12,959 $10.78 $139.7K $0 10 2025-05-07
Allergan plc (AGN) Delisted Director 0 — — $0 4 2020-05-11
MEDICINES CO /DE (MDCO) Delisted Director 163,431 — — $0 16 2017-11-13
CELGENE CORP /DE/ (CELGZ) Delisted see remarks 1,069,706 — — -$70.81M 50 2017-10-31
DHR Director 3,576 $229.04 $819.0K $0 3 2017-05-17
CELGENE CORP /DE/ (CELG) Delisted Chief Executive Officer 1,470,028 — — -$89.43M 24 2010-10-14
Coley Pharmaceutical Group, Inc. (COLY) Delisted Director — — — $0 1 2007-06-15

Recent Filings · Page 12 of 12

117 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2007-07-11 CELGENE CORP /DE/ (CELG) Delisted Grant (A) — $0 EDGAR
2007-06-15 Coley Pharmaceutical Group, Inc. (COLY) Delisted Grant (A) — $0 EDGAR
2007-06-08 CELGENE CORP /DE/ (CELG) Delisted Sell (S) −195,490 -$11.55M EDGAR
2007-05-29 MEDICINES CO /DE (MDCO) Delisted Grant (A) +3,750 $0 EDGAR
2007-04-11 CELGENE CORP /DE/ (CELG) Delisted Grant (A) — $0 EDGAR
2007-01-18 MEDICINES CO /DE (MDCO) Delisted Exer (M) +18,333 $315.1K EDGAR
2007-01-10 CELGENE CORP /DE/ (CELG) Delisted Grant (A) — $0 EDGAR
Showing 111–117 of 117
Page 12 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.